Results 41 to 50 of about 70,285 (179)

Background-Quenched Aggregation-Induced Emission through Electrostatic Interactions for the Detection of Poly(ADP-ribose) Polymerase-1 Activity

Molecules, 2023
Poly(ADP-ribose) polymerase-1 (PARP1) is a potential biomarker and therapeutic target for cancers that can catalyze the poly-ADP-ribosylation of nicotinamide adenine dinucleotide (NAD+) onto the acceptor proteins to form long poly(ADP-ribose) (PAR ...
Fengli Gao, Ruimin Zhao, Liping Huang, Xinyao Yi   +3 more
doaj   +1 more source

PARP-3 and APLF function together to accelerate nonhomologous end joining [PDF]

, 2010
PARP-3 is a member of the ADP-ribosyl transferase superfamily of unknown function. We show that PARP-3 is stimulated by DNA double-strand breaks (DSBs) in vitro and functions in the same pathway as the poly (ADP-ribose)-binding protein APLF to accelerate
Ahel, Ame, Anna E.O. Fisher, Audebert, Bekker-Jensen, Benjamin, Bernardo Reina-San-Martin, Boulton, Brown, Bryant, Bryant, Caldecott, Caldecott, Critchlow, Ding, Drouet, El-Khamisy, Farmer, Fisher, Grawunder, Guy Poirier, Hochegger, Hottiger, Iles, Isabelle Robert, Kanno, Keith W. Caldecott, Kickhoefer, Kleine, Le Page, Lehtio, Limei Ju, Lobrich, Loseva, Macrae, Mahaney, Maria C. Zuma, Mehrotra, Michele Rouleau, Morrison, Okano, Otto, Poirier, Robert, Roberts, Rogakou, Rogakou, Rouleau, Rulten, Smith, Soulas-Sprauel, Stevnsner, Stuart L. Rulten, Sugimura, Trucco, Wang, Yan, Yang, Yano, Yano   +59 more
core   +1 more source

Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer

Clinical Genitourinary Cancer, 2023
Poly ADP-ribose polymerase inhibitors (PARPis) have clinical activity in several cancers. The rationale of their therapeutic use in urothelial cancer (UC) resides in the high homologous-recombination repair (HRR) deficiency (HRD) prevalence and potential cross-sensitivity with platinum-based chemotherapy (PBCT).
Gamba, Teresa, Paparo, Jessica, Panepinto, Olimpia, Dionisio, Rossana, Di Maio, Massimo, Vignani, Francesca   +5 more
openaire   +2 more sources

Methylation status of Dnmt1 promoter depends on poly(ADP-ribosy)lation [PDF]

, 2007
Research is focused on CpG islands and on the mechanism that poly(ADP-ribosyl)ation uses to defend the unmethylated state of these important DNA sequences which are located in the promoter regions of the housekeeping genes having a role of transcription ...
Zampieri, Michele
core   +1 more source

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Clinical and Translational Radiation Oncology, 2020
Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when ...
David S. Lakomy, Diana L. Urbauer, Shannon N. Westin, Lilie L. Lin   +3 more
doaj   +1 more source

Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib [PDF]

, 2018
Upon DNA binding the poly(ADP-ribose) polymerase family of enzymes (PARPs) add multiple ADP-ribose subunits to themselves and other acceptor proteins.
Albert, Ali, Ame, Amit Nathubhai, Audebert, Barkauskaite, Beck, Benhur, Benjamin, Blenn, Boehler, Boulton, Braun, Bridges, Brochu, Bryant, Bryant, Bryant, Calabrese, Chalmers, Chang, Chang, Chang, Chow, Cortes, deMurcia, Ding, Dominic I. James, Donawho, Drean, Dungey, Dungey, Efimova, El-Khamisy, Emma Grant, Erdelyi, Fabbro, Fathers, Feng, Feng, Feng, Fisher, Godon, Gravells, Ha, Helen E. Bryant, Huang, Illuzzi, James, James Neale, Kate M. Smith, Khan, Kim, Le Page, Lee, Lomax, Martin, Medvedeva, Min, Miwa, Morrison, Mueller, Nakadate, Nathubhai, Noel, Okano, Oplustil O'Connor, Ozaki, Polly Gravells, Ray Chaudhuri, Rothkamm, Rulten, Rulten, Saleh-Gohari, Schlicker, Schreiber, Senra, Shall, Shelton, Shirai, Shirai, Slade, Strom, Sugimura, Tripathi, Trucco, Venere, Wang, Wang, Wang, Wieler, Yang, Yeh, Yoshikawa, Zhu   +94 more
core   +2 more sources

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

Drugs in R&D, 2020
Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and ...
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis   +8 more
doaj   +1 more source

The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors [PDF]

, 2018
No abstract ...
Gaze, Mark N., Mairs, Robert J., Nile, Donna L., Nixon, Colin, Rae, Colin   +4 more
core   +1 more source

NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression

Nature Communications, 2019
Cancer cells respond differently to inhibitors of Poly (ADP-ribose) polymerase. Here the authors reveal that ovarian cancer cells with higher cellular NADP+ levels are more sensitive to clinically relevant PARP1 inhibitors and show that NADP+ act as an ...
Chunjing Bian, Chao Zhang, Tao Luo, Aditi Vyas, Shih-Hsun Chen, Chao Liu, Muzaffer Ahmad Kassab, Ying Yang, Mei Kong, Xiaochun Yu   +9 more
doaj   +1 more source

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]

, 2016
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide, Papa, Anselmo, Strudel, Martina, Tomao, Federica, Tomao, Silverio   +4 more
core   +2 more sources